JP2024023294A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023294A5 JP2024023294A5 JP2023193282A JP2023193282A JP2024023294A5 JP 2024023294 A5 JP2024023294 A5 JP 2024023294A5 JP 2023193282 A JP2023193282 A JP 2023193282A JP 2023193282 A JP2023193282 A JP 2023193282A JP 2024023294 A5 JP2024023294 A5 JP 2024023294A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- cells
- homology arm
- nucleic acid
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762597118P | 2017-12-11 | 2017-12-11 | |
| US62/597,118 | 2017-12-11 | ||
| US201862623501P | 2018-01-29 | 2018-01-29 | |
| US62/623,501 | 2018-01-29 | ||
| US201862664905P | 2018-04-30 | 2018-04-30 | |
| US62/664,905 | 2018-04-30 | ||
| US201862746494P | 2018-10-16 | 2018-10-16 | |
| US62/746,494 | 2018-10-16 | ||
| JP2020531964A JP2021505187A (ja) | 2017-12-11 | 2018-12-11 | 遺伝子編集のためのｃｐｆ１関連方法及び組成物 |
| PCT/US2018/065032 WO2019118516A1 (en) | 2017-12-11 | 2018-12-11 | Cpf1-related methods and compositions for gene editing |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531964A Division JP2021505187A (ja) | 2017-12-11 | 2018-12-11 | 遺伝子編集のためのｃｐｆ１関連方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024023294A JP2024023294A (ja) | 2024-02-21 |
| JP2024023294A5 true JP2024023294A5 (enExample) | 2025-06-24 |
Family
ID=65023985
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531964A Pending JP2021505187A (ja) | 2017-12-11 | 2018-12-11 | 遺伝子編集のためのｃｐｆ１関連方法及び組成物 |
| JP2023193282A Pending JP2024023294A (ja) | 2017-12-11 | 2023-11-13 | 遺伝子編集のためのｃｐｆ１関連方法及び組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531964A Pending JP2021505187A (ja) | 2017-12-11 | 2018-12-11 | 遺伝子編集のためのｃｐｆ１関連方法及び組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200299661A1 (enExample) |
| EP (1) | EP3724326A1 (enExample) |
| JP (2) | JP2021505187A (enExample) |
| KR (1) | KR20200097760A (enExample) |
| CN (1) | CN111712569A (enExample) |
| AU (1) | AU2018383712B2 (enExample) |
| CA (1) | CA3085338A1 (enExample) |
| MX (1) | MX2020006072A (enExample) |
| WO (1) | WO2019118516A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018170184A1 (en) | 2017-03-14 | 2018-09-20 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| WO2018209158A2 (en) | 2017-05-10 | 2018-11-15 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| SG11202008956XA (en) * | 2018-03-14 | 2020-10-29 | Editas Medicine Inc | Systems and methods for the treatment of hemoglobinopathies |
| US12133884B2 (en) | 2018-05-11 | 2024-11-05 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| US20200216825A1 (en) * | 2019-01-08 | 2020-07-09 | Integrated Dna Technologies, Inc. | CAS12a MUTANT GENES AND POLYPEPTIDES ENCODED BY SAME |
| AU2020223060B2 (en) * | 2019-02-13 | 2023-04-13 | Beam Therapeutics Inc. | Compositions and methods for treating hemoglobinopathies |
| EP4047087A4 (en) * | 2019-08-19 | 2023-08-23 | Southern Medical University | Construction of high-fidelity crispr/ascpf1 mutant and application thereof |
| JP7696335B2 (ja) * | 2019-09-09 | 2025-06-20 | スクライブ・セラピューティクス・インコーポレイテッド | 免疫療法に使用するための組成物および方法 |
| US20230009232A1 (en) * | 2019-11-20 | 2023-01-12 | Cartherics Pty. Ltd. | Method for providing immune cells with enhanced function |
| CN111647618A (zh) * | 2020-01-15 | 2020-09-11 | 温州医科大学 | 一种新型基因组编辑工具（Lb2Cas12a-RVR）及其构建方法和应用方法 |
| CN113355389B (zh) * | 2020-03-05 | 2022-11-15 | 广西扬翔股份有限公司 | 利用CRISPR/Cas12a系统靶向富集核酸目标区域的方法及其应用 |
| EP4146800A1 (en) * | 2020-05-08 | 2023-03-15 | Metagenomi, Inc. | Enzymes with ruvc domains |
| KR20220005208A (ko) * | 2020-07-06 | 2022-01-13 | 주식회사 지씨셀 | 면역원성이 감소된 신규한 이식용 세포 |
| KR102497690B1 (ko) * | 2020-09-22 | 2023-02-10 | (주)지플러스생명과학 | 신규한 crispr 연관 단백질 및 이의 용도 |
| US20230374478A1 (en) * | 2020-09-22 | 2023-11-23 | G Flas Life Sciences | Modified cas12a protein and use thereof |
| US20230416732A1 (en) * | 2020-10-30 | 2023-12-28 | Arbor Biotechnologies, Inc. | Compositions comprising an rna guide targeting bcl11a and uses thereof |
| AU2021369840A1 (en) * | 2020-10-30 | 2023-06-01 | Arbor Biotechnologies, Inc. | Compositions comprising an rna guide targeting b2m and uses thereof |
| US20240026351A1 (en) * | 2020-10-30 | 2024-01-25 | Arbor Biotechnologies, Inc. | Compositions comprising an rna guide targeting trac and uses thereof |
| WO2022103935A1 (en) * | 2020-11-11 | 2022-05-19 | The Trustees Of Columbia University In The City Of New York | Multiplex epigenome editing |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021396403A1 (en) * | 2020-12-11 | 2023-06-29 | Intellia Therapeutics, Inc. | Compositions and methods for reducing mhc class ii in a cell |
| EP4259160A4 (en) * | 2020-12-14 | 2025-05-14 | Emendobio Inc. | BIALLELIC INACTIVATION OF B2M |
| KR20230135068A (ko) * | 2020-12-23 | 2023-09-22 | 인텔리아 테라퓨틱스, 인크. | 세포에서 ciita를 유전적으로 변형시키기 위한 조성물및 방법 |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| CN112725487A (zh) * | 2021-02-03 | 2021-04-30 | 张国良 | 用于链霉素耐药结核分枝杆菌的核酸快速检测试剂盒及其检测方法 |
| US20240200059A1 (en) | 2021-04-09 | 2024-06-20 | Vor Biopharma Inc. | Photocleavable guide rnas and methods of use thereof |
| WO2022236147A1 (en) * | 2021-05-06 | 2022-11-10 | Artisan Development Labs, Inc. | Modified nucleases |
| KR102787489B1 (ko) * | 2021-06-16 | 2025-03-31 | 한국생명공학연구원 | enCpf1 및 키메릭 DNA-RNA 가이드를 포함하는 유전체 교정 또는 발현 억제용 조성물 |
| US20230016422A1 (en) * | 2021-06-23 | 2023-01-19 | Crispr Therapeutics Ag | Engineered cells with improved protection from natural killer cell killing |
| WO2023283585A2 (en) | 2021-07-06 | 2023-01-12 | Vor Biopharma Inc. | Inhibitor oligonucleotides and methods of use thereof |
| WO2023004411A1 (en) * | 2021-07-23 | 2023-01-26 | Icahn School Of Medicine At Mount Sinai | A method for in vivo gene therapy to cure scd without myeloablative toxicity |
| US20250122534A1 (en) | 2021-08-02 | 2025-04-17 | Vor Biopharma Inc. | Compositions and methods for gene modification |
| WO2023028348A1 (en) | 2021-08-27 | 2023-03-02 | Metagenomi, Inc. | Enzymes with ruvc domains |
| US20240417755A1 (en) | 2021-09-27 | 2024-12-19 | Vor Biopharma Inc. | Fusion polypeptides for genetic editing and methods of use thereof |
| WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
| CN116144631B (zh) * | 2023-01-17 | 2023-09-15 | 华中农业大学 | 耐热型核酸内切酶及其介导的基因编辑系统 |
| US20240254463A1 (en) * | 2023-02-01 | 2024-08-01 | Vedabio, Inc. | Engineered stable nucleic acid-guided nucleases |
| CN116179513B (zh) * | 2023-03-10 | 2023-12-22 | 之江实验室 | 一种Cpf1蛋白及其在基因编辑中的应用 |
| CN116179511B (zh) * | 2023-03-10 | 2023-12-22 | 之江实验室 | Cpf1蛋白在制备用于核酸检测的试剂盒中的应用 |
| WO2024249346A1 (en) | 2023-05-26 | 2024-12-05 | Editas Medicine, Inc. | Crispr-related methods and compositions targeting cd70 expression |
| WO2024249342A1 (en) | 2023-05-26 | 2024-12-05 | Editas Medicine, Inc. | Crispr-related methods and compositions targeting ptpn2 expression |
| WO2024249348A2 (en) | 2023-05-26 | 2024-12-05 | Editas Medicine, Inc. | Crispr-related methods and compositions targeting fl1-1 expression |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080569A (en) * | 1993-06-24 | 2000-06-27 | Merck & Co., Inc. | Adenovirus vectors generated from helper viruses and helper-dependent vectors |
| US5994627A (en) | 1995-03-31 | 1999-11-30 | Common Wealth Scientific And Industrial Research Organisation | Genetic sequences conferring nematode resistance in plants and uses therefor |
| CA2329947A1 (en) * | 1998-06-09 | 1999-12-16 | Merck & Co., Inc. | Novel adenoviral vectors for gene therapy |
| WO2009131632A1 (en) * | 2008-04-14 | 2009-10-29 | Sangamo Biosciences, Inc. | Linear donor constructs for targeted integration |
| GB201013153D0 (en) | 2010-08-04 | 2010-09-22 | Touchlight Genetics Ltd | Primer for production of closed linear DNA |
| BR112014027813A2 (pt) | 2012-05-07 | 2017-08-08 | Dow Agrosciences Llc | métodos e composições para integração de transgenes direcionada mediada por nuclease |
| US9540659B2 (en) * | 2012-07-06 | 2017-01-10 | University Of Iowa Research Foundation | Modified adeno-associated virus vector compositions |
| EP2970943A4 (en) * | 2013-03-15 | 2017-04-19 | The Children's Hospital of Philadelphia | Vectors comprising stuffer/filler polynucleotide sequences and methods of use |
| US10494645B2 (en) * | 2013-04-18 | 2019-12-03 | Fondazione Telethon | Effective delivery of large genes by dual AAV vectors |
| KR20230054509A (ko) | 2013-11-07 | 2023-04-24 | 에디타스 메디신, 인코포레이티드 | 지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물 |
| EP3553176A1 (en) | 2014-03-10 | 2019-10-16 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) |
| EP4427809A3 (en) * | 2014-10-31 | 2024-12-04 | The Trustees of The University of Pennsylvania | Altering gene expression in car-t cells and uses thereof |
| AU2015342749B2 (en) | 2014-11-07 | 2022-01-27 | Editas Medicine, Inc. | Methods for improving CRISPR/Cas-mediated genome-editing |
| US20160362667A1 (en) * | 2015-06-10 | 2016-12-15 | Caribou Biosciences, Inc. | CRISPR-Cas Compositions and Methods |
| WO2017011519A1 (en) * | 2015-07-13 | 2017-01-19 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| GB2557123B (en) * | 2015-07-31 | 2021-11-03 | Univ Minnesota | Modified cells and methods of therapy |
| US12110490B2 (en) * | 2015-12-18 | 2024-10-08 | The Broad Institute, Inc. | CRISPR enzymes and systems |
| SG11201807538PA (en) * | 2016-03-04 | 2018-09-27 | Editas Medicine Inc | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy |
| IL313038A (en) * | 2016-03-14 | 2024-07-01 | Editas Medicine Inc | Methods and preparations related to CRISPR/CAS - for the treatment of diseases in the hemoglobin cell |
| SG11201809144XA (en) * | 2016-04-18 | 2018-11-29 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
| WO2017189308A1 (en) * | 2016-04-19 | 2017-11-02 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| KR102424476B1 (ko) * | 2016-04-19 | 2022-07-25 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규한 crispr 효소 및 시스템 |
| EP3652312A1 (en) * | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| WO2019084168A1 (en) * | 2017-10-24 | 2019-05-02 | Editas Medicine, Inc. | SYSTEMS AND METHODS FOR TREATING HYPER-IGM SYNDROME |
| EP3707266A1 (en) * | 2017-11-07 | 2020-09-16 | Editas Medicine, Inc. | Targeted integration systems and methods for the treatment of hemoglobinopathies |
-
2018
- 2018-12-11 EP EP18834094.7A patent/EP3724326A1/en active Pending
- 2018-12-11 AU AU2018383712A patent/AU2018383712B2/en active Active
- 2018-12-11 MX MX2020006072A patent/MX2020006072A/es unknown
- 2018-12-11 JP JP2020531964A patent/JP2021505187A/ja active Pending
- 2018-12-11 CA CA3085338A patent/CA3085338A1/en active Pending
- 2018-12-11 KR KR1020207019710A patent/KR20200097760A/ko active Pending
- 2018-12-11 WO PCT/US2018/065032 patent/WO2019118516A1/en not_active Ceased
- 2018-12-11 CN CN201880089010.3A patent/CN111712569A/zh active Pending
-
2020
- 2020-06-11 US US16/899,302 patent/US20200299661A1/en active Pending
-
2023
- 2023-11-13 JP JP2023193282A patent/JP2024023294A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024023294A5 (enExample) | ||
| US12398193B2 (en) | Targeted replacement of endogenous T cell receptors | |
| US11008587B2 (en) | Universal donor cells | |
| CN114375301B (zh) | 工程改造的t细胞 | |
| CN110139675B (zh) | 用具有工程化稳定的内源性foxp3基因表达的cd4t细胞治疗自身免疫疾病的方法 | |
| JP2024009129A (ja) | サイトカイン誘導性ｓｈ２含有タンパク質（ｃｉｓｈ）遺伝子の遺伝子改変 | |
| CN111918659A (zh) | 原代细胞基因编辑 | |
| JP2024041866A (ja) | 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法 | |
| JP2021520844A (ja) | 操作されたカスケード構成要素およびカスケード複合体 | |
| CN105208866A (zh) | 使用工程化锌指蛋白核酸酶靶向断裂t细胞受体基因 | |
| JP2022547053A (ja) | ユニバーサルドナー細胞 | |
| CN114375300A (zh) | 通用供体细胞 | |
| US20230323309A1 (en) | Universal donor cells | |
| CN112725379A (zh) | 人源化cd40基因改造动物模型的构建方法及应用 | |
| US20240424023A1 (en) | Method | |
| Mueller et al. | CRISPR-mediated insertion of a chimeric antigen receptor produces nonviral T cell products capable of inducing solid tumor regression | |
| WO2024238689A2 (en) | Compositions and methods for multiplex epigenetic regulation | |
| JP2024534003A (ja) | 細胞ベースの治療法に向けた細胞の操作、ならびに関連する組成物及び方法 | |
| CN116887853A (zh) | 用于定点诱变的组合物和方法 | |
| HK40036145B (zh) | 原代细胞基因编辑 | |
| HK40058224A (en) | Universal donor cells | |
| HK40058224B (en) | Universal donor cells | |
| BR112020008201B1 (pt) | Método in vitro ou ex vivo para edição do genoma de uma célula t humana primária, composição, população de células t, e uso de uma célula t |